OxThera has recently been granted two new US patents, three new Europeanpatents and patents in Canada, China, Hong-Kong, India and Japan.

OxThera now holds proprietary rights to pharmaceutical preparations and their use for treatment of hyperoxaluria in nine patent families. The newly granted US patents have numbers US8900575 and US8940295 covering pharmaceutical compositions of oxalate decarboxylase. The new European patents have numbers EP2449098 covering pharmaceutical compositions of oxalate decarboxylase, EP1771201 and EP1965816 covering pharmaceutical compositions of Oxalobacter formigenes. Patents in Canada, China, Hong-Kong, India and Japan have numbers CA2650122, CN ZL201080029636.9, HK1128871, IN263959 and JP5558002.

“These patents covering pharmaceutical compositions and methods for treating and preventing oxalate-related disease with enzymes and bacteria, further strengthen the company’s patent estate and worldwide rights for the treatment of hyperoxaluria,” said Matthew Gantz, CEO of OxThera.

Oxabact is an oral product composed of highly concentrated live bacteria (Oxalobacter formigenes). OxThera is currently pursuing a complete Oxabact clinical development program for the treatment of patients suffering from Primary Hyperoxaluria. Oxazyme is an oral enzyme, oxalate decarboxylase. The product is designed to break down dietary oxalate in the upper GI tract. The product is developed to treat hyperoxaluria and kidney stones caused by excess intake of dietary oxalate.